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Quetiapine is an atypical antipsychotic approved for the treatment of patients with psychotic disorders. Since approvement
several case reports about intoxication with quetiapine were linked mainly with tachycardia, QTc-prolongation, somnolence,
and hyperglycemia. Here, we present the ﬁrst case report of an intoxication with an extreme overdose of quetiapine (36g),
ingested by a 32-year-old female (62kg bodyweight) to attempt suicide. Symptoms associated with intoxication were coma
without arterial hypotension, persistent tachycardia, hyperglycemia, and transient hypothyreoidism. QTc-interval was moderately
extended. Management consisted of intubation for airway protection, gastric lavage, the use of activated charcoal, i.v. saline, and
observation for 17 hours on an intensive care unit. Despite the extremely high dose of quetiapine, the patient recovered completely
without residual symptoms.
Copyright © 2009 C. M¨ uller et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Quetiapine is indicated and approved for the treatment of
psychotic disorders in adults by the U.S. Food and Drug
Administration. The eﬃcacy of quetiapine in the treatment
of acute mania and depression associated with bipolar
disorder and the therapy of schizophrenia with quetiapine
h a sb e e np r o v e di nr a n d o m i z e dc o n t r o l l e dt r i a l s( f o rr e v i e w ,
see [1]).
Pharmacokinetics and pharmacodynamics of quetiap-
ine fumarate (Seroquel), a dibenzothiazepine antipsychotic
agent bearing structural similarity to clozapine and olan-
zapine, have previously been described and reviewed [2–
4]. After oral administration the drug is eliminated with a
mean terminal half-life of approximately 7 hours [1]. The
volume of distribution and total protein binding is 10l/kg
and83%,respectively(Prod.InfoSeroquel,2004a).Thedrug
is primarily metabolized by sulfoxidation and oxidation with
the CYP3A4 isoenzyme and the 7-hydroxylated as well as
the N-dealkylated metabolite are pharmacologically active
[2].
Quetiapine shows aﬃnity for multiple neurotransmitter
receptors in in vitro binding studies. The drug exhibits high
aﬃnity for serotonergic 5-HT2A-receptors and moderate
aﬃnity for dopamine D2-receptors; whereas antagonism of
D1- and 5-HT1A-receptors is relatively weak. The antipsy-
chotic eﬀect is explained by the antagonistic eﬀect on D2-
receptors and 5-HT2A-receptors [5].
Appreciable aﬃnity for α1-adrenergic, α2-adrenergic,
and histamine H1-receptors has also been observed [6].
Adverse eﬀects even at the beginning of the therapy like
sedation and somnolence are explained by antagonism of
histamine H1-receptors. Orthostatic dysregulation, hypoten-
sion, and tachycardia are associated with an antagonistic
eﬀect on α1-adrenergic receptors. Quetiapine has also been
reported to have an antagonistic eﬀect on M1-muscarinic
receptors resulting in anticholinergic mediated tachycardia
[1, 7].
Quetiapine and other atypical antipsychotic drugs like
clozapine or olanzapine provide antipsychotic eﬃcacy with
a lower risk of EPS compared to typical antipsychotics,
but atypical antipsychotics are associated with a variety2 Case Reports in Medicine
of metabolic and cardiovascular adverse eﬀects particularly
with regard to an overdose [8–15]. If treating patients with
quetiapineoneshouldbefamiliarwiththeclinicalsymptoms
of quetiapine intoxication and its treatment. Here, we report
on clinical eﬀects of an extreme quetiapine overdose and
how such an intoxication can be survived under appropriate
treatment.
2.CaseReport
We report on a 32-year-old female (62kg bodyweight)
with history of paranoid-hallucinatory schizophrenia and
depression who was discovered by her companion in life
26 hours after ingestion of 36g quetiapine (120 tablets
of 100mg and 80 tablets of 300mg) and a suspected
abuse of lorazepam. A previous suicide had been attempted
10 years before with haloperidol. Her past medical his-
tory was negative for cardiac dysrhythmia, hypertensive
heart disease or a thyroid dysfunction. The emergency
medical service found the patient comatose with response
only to deep painful stimuli (Glasgow Coma Scale of
9), normotensive (127/83mmHg), hyperglycemic capillary
glucose level: 8.96mmol/L = 160mg/dl and tachycardiac
with sinustachycardia of 140bpm, capillary oxygen satu-
ration was 98% and respiratory rate 12/min. There was
no evidence of trauma or infection. During the transport
to the hospital 40mg of furosemide and 1000mL saline
were administered intravenously for detoxiﬁcation and
prophylaxis of hypotension. Vital signs were stable during
transport.
On admission on the intensive care unit (ICU) the
patient’s condition worsened and she was intubated for
airway protection. At this time venous blood gas on 30%
FiO2 revealed pH of 7.38, pO2 of 45.3mmHg, pCO2
42.2mmHg, HCO
−
3 24.4mmol/L, base excess −0.1mmol/L,
Hb 13.8g/dl, K+ 3,7mmol/L, Na+ 140mmol/L.
To prevent her from further absorption of quetiapine a
gastric lavage was performed (no pill fragments of ingested
tabletswererecovered)andthepatiententerallyreceived25g
of activated charcoal with 5g Glauber’s salt (sodium sulfate)
every 3 to 4 hours until dejection of black stool.
Laboratory data on admission including serum elec-
trolytes, liver, and renal function parameters and blood
count remained normal except glucose of 8.12mmol/L
(145mg/dl), CK of 333U/L (control value remained
unchanged) with no evidence of myocardial insuﬃciency
or infarction, CRP of 32mg/L (control value 8 hours later
increased to 76mg/L), TSH 6.0mU/L (control value 8 hours
later increased to 8.56mU/L), and leucocytosis with 12.06
(×109/L).
The electrocardiogram at 36 hours postingestion re-
vealed a moderately extended QTc interval measuring 436
millisseconds (at the upper limit of normal) compared to
QTc intervalof388msaftercompleterecovery.QTc-intervals
were calculated using the Bazett formula [16].
A comprehensive drug screen via immunoassay was
positive for tricyclic antidepressants and benzodiazepines in
particular, although these results could not be conﬁrmed by
UV-HPLC-methods.
Time-concentration-proﬁle, quetiapine-intoxication



























Figure 1: Serum time-concentration proﬁle of quetiapine after
ingestion of an assumed amount of 36g Seroquel in a 32-year-old
female patient. Solid-line: ﬁtted line based on a two-compartment
model assuming a reduced resorption. Dotted line: ﬁtted line
expected by population pharmacokinetic parameters and normal
resorption.
One day after admission cardiac and pulmonary status
was stable (without signs of QTc-prolongation, arrhythmia,
or tachycardia), state of consciousness improved, so that
she could be extubated and was transferred to psychiatric
crisis ward within 67 hours after ingestion of quetiapine. The
increased levels for glucose and TSH lasted for 2.5 days, CK
turned to normal after 6 days and CRP after roughly two
weeks, respectively (see Table 1).
Serum-samples for pharmacokinetic analysis were col-
lected directly on arrival in the emergency department, 5
hours after admission and the following two days (four
samples in total). Quetiapine serum concentrations were
determined by a validated UV-HPLC-method (linearity
range 0.03–4.00mg/L, lower limit of quantiﬁcation (LLOQ)
0.03mg/L, limit of detection (LOD) 0.01mg/L). Drug con-
centrations and patient’s data (gender, age, weight, height) as
wellastheingestedamountofquetiapinewereprocessedbya
commonly used pharmacokinetic program Mw/Pharm 3.50
[17]. Pharmacokinetic parameters were investigated based
on an open two-compartment model and a Bayesian ﬁtting
procedure.
Elimination half-life was calculated as follows:
− t1/2 = ln2/λz (elimination, λz is the rate constant
corresponding to the terminal elimination).
Figure 1 exempliﬁes the obtained quetiapine concentra-
tion levels and the software generated time-concentration
proﬁle based on a two-compartment model (solid-line). In
addition, the expected time-concentration proﬁle based on
population-pharmacokinetic data is shown (dotted line).
Absorption was supposed to be reduced because of anti-
cholinergic eﬀects of quetiapine on intestinal tract.
The elimination half-life was t1/2 = 5.3h o u r sa n d
was calculated based on the four obtained quetiapine
concentration levels (c1 = 4.22mg/L; c2 = 2.77mg/L; c3 =
0.06mg/L; c4 = 0.06mg/L) with regard to patient’s medical
records and displayed a moderately increased eliminationCase Reports in Medicine 3
Table 1
Parameter Time after ingestion of quetiapine
26 h 28 h 29 h 32 h 37 h 51 62 h 140 h 331 h
Laboratory data:
Quetiapine, μg/L 4220 2770 64 64
Na+, mmol/L 137 140 141 138 138
K+, mmol/L 3.6 4.6 4.0 3.6 4.3
Cl−, mmol/L 123 116 105 105
Glucose, mmol/L 8.96 8.12 5.94 5.04 5.66 5.49
CK, U/L 333 317 355 69 66
Leucocytes (×109/L) 12.06 6.61 6.23 6.21 5.46
CRP, mg/L 32 76 96 11 <3
Free T3, ng/L 2.8 2.1 2.6
Free T4, ng/L 18.6 14.1 12.0
TSH, mU/L 6.04 8.56 3.35
Vital parameters:
BP syst., mmHg 127 110 120 130 130
BP diast., mmHg 83 70 80 70 70
HR, beats/min 140 120 90 85 85
RR, resp./min 12 12 8 8
QTc [ms] 436 404 388
CK: creatin kinase, CRP: c-reactive protein, T3: triiodothyronine, T4: tetraiodothyronine, TSH: thyroid-stimulating hormone, BP: blood pressure, HR: heart
rate, RR: respiratory rate, QTc: cardiac QT interval (at a standardized heart rate of 60/minute).
compared to population pharmacokinetic parameters. Addi-
tionally, the absorption rate constant ka (time)−1 had to be
adjusted and displayed a reduced absorption of quetiapine
after ingestion. In this case the patient was supposed to
have ingested 36g quetiapine corresponding to a dosage of
580mg/kg quetiapine. Volume of distribution was within
the expected range (Vd = 9L/kg based on ﬁtted solid line,
Figure 1).
Expectedpeakquetiapineconcentrationsforpopulation-
pharmacokinetic data were higher than the ﬁtted time-
concentration proﬁle based on measured quetiapine concen-
trations and a two-compartment model.
3. Discussion
This is the ﬁrst case report of an intoxication with such
an extremely high amount of quetiapine (580mg/kg).
Remarkable side eﬀects were tachycardia, somnolence,
hyperglycemia, transient hypothyroidism, and a moderately
prolonged QTc-interval, but the patient survived and fully
recovered.
Side eﬀects: tachycardia is most likely explained by an
anticholinergic eﬀect of quetiapine [7].
Symptoms of central nervous depression (somnolence,
drowsiness) are primarly mediated through antagonistic
eﬀect of quetiapine on serotonergic 5-HT2A-a n dm o d e r a t e
antagonistic eﬀect on dopamine type 2 D2-receptors. Pro-
longed tachycardia is usually explained by an antagonistic
eﬀect of quetiapine on α1-receptors [7]. Generally, the
adverse eﬀects like tachycardia, hyotension, and somnolence
associated with quetiapine in particular after ingestion of
an overdose can be explained by blockage of the alpha-
adrenergic, muscarinic, and histamine receptors [1].
In recent publications surprisingly no statement about
additional blood glucose laboratory data was provided,
although several case reports after ingestion of high dosages
of quetiapine were presented [7, 9].
The mechanism for hyperglycemia may be related to
5-HT2-receptor antagonism, which is associated not only
with weight gain but also with hyperglycemia [18, 19]. 5-
HT2-receptor antagonists can signiﬁcantly decrease insulin
sensitivity, an eﬀect possibly mediated by the suppression of
5-HT2A-receptor-mediated glucose uptake in skletal muscle
[8, 20]. For instance, 5-HT2C knockout mice develop insulin
resistance and impaired glucose tolerance and show severe
weight gain [21]. This may be a likely mechanism for
hyperglycemia in the therapy with atypical antipsychotics
and in case of quetiapine overdose.
Moreover antipsychotic drug aﬃnity and antagonistic
eﬀects on muscarinic receptors are signiﬁcant predictors
of the development of diabetes. Muscarinic M3-receptors
are highly expressed by pancreatic β-cells and antagonism
leads to dysregulation of glucose-dependent acetylcholin
modulation of insulin secretion [22].
Suppression of compensatory insulin release may explain
hyperglycemia in the present case report of quetiapine
overdose.
Summarized, three receptor mediated mechanisms are
commonly supposed for glucosedysregulation in particular
after intoxication with an atypical antipsychotic.
First, 5-HT2A-receptor antagonism: suppression of
receptor-mediated glucose uptake in skeletal muscle.4 Case Reports in Medicine
Second, 5-HT2C-antagonism is correlated with an
increased risk of diabetes and weight gain most likely
explained by 5-HT2C-receptor mediated insulin resistence
and impaired glucose tolerancelinebreak [21].
Third, M3-receptor-antagonism: dysregulation of
glucose-dependent acetylcholin modulation of insulin secre-
tion.
Hypothyroidism. Hypothyroidism associated with quetiap-
ine treatment has been reported in previous studies under
treatment with a normal daily dosage of quetiapine [23–
26]. Although the mechanism is not known a competitive
metabolism of thyroid hormones and quetiapine by UDP-
glucoronyltransferase has been suggested as a plausible
mechanism for a decrease of thyroid hormones during
quetiapine treatment [25].
In case of a patient with compromised thyroid function
receiving treatment with quetiapine may develop hypothy-
roidism and clinicians should consider routine monitoring
of thyroid function [23].
Observed Quetiapine Concentrations and Pharmacoki-
netics. In our case report the measured serum concen-
trations of quetiapine were lower than the expected que-
tiapine concentrations due to the absorption rate con-
stant, ka (time)−1 and displayed a reduced absorption of
quetiapine after ingestion (Figure 1). These ﬁndings are
consistent with previously ﬁndings [11, 12]. Lower than
expected peak concentrations may be explained by potential
anticholinergic eﬀects of quetiapine reducing absorption.
With regard to a delayed absorption the expected time
to maximum quetiapine concentration is supposed to be
prolonged in these cases. In contrast to the ﬁndings of
Hunfeld et al. we determined a serum time-concentration
proﬁle lower than the expected one. We assume that
the impacts of side eﬀects after ingestion of a very high
amount of quetiapine may have contributed a decreased
absorption with no inﬂuence on terminal elimination
half-life.
With regards to the rescue case protocol the patient
is supposed to have ingested 36g quetiapine (rescue
operation record: 120 tablets of 100mg and 80 tablets
of 300mg). Although it cannot be ruled out that the
ingested amount might have been less than 36g, the time-
concentration proﬁle in this case is based on reduced
absorption.
In contrast to these explanations the reason for consid-
erably lower than expected quetiapine concentrations could
obviously be an ingestion of a much lower amount of about
18g quetiapine.
A comprehensive drug screen via immunoassay was
positive for tricyclic antidepressants and benzodiazepines in
particular.
Though an additional spectrophotometric (UV)-HPLC-
method performed by the institute of forensic medicine did
not conﬁrm the concomitant intake of lorazepam.
Drug screening also was positive for tricyclic antidepres-
sants, although the use of immunoassays is limited, because
diﬀerent drugs of the corresponding group may have quite
diﬀerent cross reactivity and/or pharmacological potency
[27].
A comprehensive drug screening of tricyclic antidepres-
santscouldnotbeconﬁrmedinadditionalanalyseswithUV-
HPLC.
Recommendations for Management of Therapy after Que-
tiapine Intoxication. The treatment of quetiapine intoxica-
tions in case of an unknown ingested amount in particular
consists in a supportive therapy and the patients should be
monitored in an intensive care unit.
Forced Diuresis with Furosemide and Saline. Although
40mg furosemide were administered during transport, the
treatment with diuretic drugs for the purpose of enhanced
elimination is no longer recommended [28]. Moreover the
eﬃciency of this treatment is limited due to a relatively large
volume of distribution of quetiapine (Vd = 10l/kg) and a
small renal elimination rate of quetiapine (less than 5%).
In case of a hypotensive patient the administration
of diuretic drugs (e.g., furosemide) is not recommended,
because of worsening the patients condition (further
decrease of blood pressure).
Gastric Lavage after 27 Hours. To prevent further absorp-
tion of quetiapine a gastric lavage was performed and
the patient was given activated charcoal with Glauber’s
salt 27 hours after quetiapine ingestion according to the
recommendation of Burns et al.
At this time gastrointestinal passage of quetiapine is
almost completed, although charcoal and glauber’s salt
(sodium sulfate) should be administered as soon as possible,
if lag-time of drug ingestion is unknown. It should be
noted that the risk of death following atypical antipsy-
chotic overdose is very low [13]a n dg a s t r i cl a v a g ei sn o t
routinely recommended after the 60 minutes time range
[13, 29].
Monitoring of cardiac and respiratory function, intra-
venous access, and a 12-lead ECG is required [7, 13, 14].
Adminstration of intravenous magnesium sulfate (2g
bolus followed by an infusion of 2–4mg/minute) is the intial
therapy of choice regardless of serum magnesium level to
the patient with QTc prolongation. Serum potassium should
be maintained in the high-normal range (4.5–5mmol/L)
and ingested drugs as well as interfering drugs with its
metabolism have to be discontinued [30].
Monitoring of thyroid function in quetiapine treated
patients with a history of or a vulnerability to thyroid disease
is strongly recommended [31].
4. Summary
To our knowledge, the present case report is the ﬁrst
with an extremely high ingestion of quetiapine (36g).
Symptoms associated with intoxication were coma without
arterial hypotension, persistent tachycardia, hyperglycemia,
transient hypothyroidism, and a moderately extended QTc-
interval. Management of overdose consisted in primarily
supportive therapy on an intensive care unit.
In addition the present case may help us to understand
the diﬀerent side eﬀects of an atypical antipsychotic drug
with regard to receptor-pharmacological mechanisms.Case Reports in Medicine 5
Therapeuticdrugmonitoringandpharmacokineticanal-
ysis of quetiapine after intoxication displayed a moderately
increased elimination and a reduced absorption of quetiap-
ine.
Despite the extreme overdose of quetiapine the patient
exhibited a rapid clinical improvement and recovered with-
out residual symptoms.
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